NCT05665725View on ClinicalTrials.gov

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

September 27, 2023

Study Completion Date

September 6, 2024

Conditions
Non-Hodgkin Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Positron Emission Tomography

Undergo PET scan

BIOLOGICAL

Siltuximab

Given IV

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Timothy Voorhees

OTHER